Introduction
RUNX1/AML1 gene has been investigated in the pathogenesis of hematopoietic diseases, and point mutations of RUNX1 have been frequently detected in patients with various types of myeloid neoplasms.
A heterozygous germline mutation of the RUNX1 gene is known to cause familial platelet disorder with a predisposition to acute myeloid leukemia (FPD/AML), 1, 2 which is regarded as familial myelodysplastic syndromes (MDS). 3 RUNX1 mutations have been detected with high frequency in MDS, MDS following AML, 4 minimally differentiated AML M0 subtypes, 2,5-7 de novo AML without recurrent or complex karyotype, 8, 9 and myelodysplastic/myeloproliferative neoplasms (MDS/MPN). 10, 11 Furthermore, RUNX1 mutations are detected with high frequency in therapy-related or radiation-associated MDS and AML, 4, [12] [13] [14] [15] and leukemic transformation from MPN. [16] [17] [18] [19] It is intriguing how RUNX1 mutations contribute to the development of divergent hematological neoplasms. Functionally, most of the RUNX1 mutants equally show a loss of normal RUNX1
trans-activation potential. 4,12 20,21 The amino acid residues in the runt homology domain (RHD) of the RUNX1 protein that directly interact with DNA have been found to be frequent targets of amino acid replacement. 20, 21 Mutations on other amino acids close to these DNA-contact residues are also suspected to inhibit DNA binding by an obstructive side-chain or a structural change. Therefore, amino-replacement and in-frame insertion/deletion types of mutations confer loss of DNA-binding ability and trans-activation potential. RUNX1 mutations have been shown to play a pivotal role in the pathogenesis of MDS/AML in mouse bone marrow transplantation (BMT) systems. 22 Mice transduced with the D171N mutant, which harbors a mutation in the RHD of the RUNX1 gene, exhibited hyper-proliferative AML with multilineage dysplasia in collaboration with Evi1 overexpression. This impressive result indicates that RUNX1 mutations may be a cause of MDS with a leukemogenic potential.
However, mouse phenotypes do not always correspond to the clinical features of patients with the mutations. This may be partly due to differential gene circumstances, such as retrovirus integration sites or collaborating gene alterations, between mouse and human. 23, 24 As opposed to EVI1, overexpression of the polycomb group gene BMI1 is more common in MDS patients and is associated with MDS progression. 25, 26 Biological analysis using human hematopoietic cells is considered to be necessary to clarify the molecular mechanisms of the RUNX1 mutations in the pathogenesis of MDS. Enforced gene expression in human CD34 + cells has been utilized to investigate the role of leukemogenic oncogenes in leukemogenesis. [27] [28] [29] [30] [31] [32] [33] [34] [35] For personal use only. at Sistema Bibliotecario d'Ateneo -Università degli Studi di Bologna on bloodjournal.hematologylibrary.org From -4 -In this study, using enforced gene expression in human CD34 + cells, we demonstrated that the D171N mutant, the most frequent target of mutation in RUNX1 gene, has an increased self-renewal capacity, blocked differentiation, dysplasia in all 3 lineages, and tendency for immaturity, but no proliferation ability. Moreover, we revealed that BMI1 overexpression collaborates with RUNX1 mutations and confers proliferation ability to D171N-mutated cells, which was confirmed in both human and mouse hematopoietic stem/progenitor cells. Our results indicate that BMI1 overexpression is one of the second hit partner genes of RUNX1 mutations in the development of MDS.
For personal use only. at Sistema Bibliotecario d'Ateneo -Università degli Studi di Bologna on bloodjournal.hematologylibrary.org From -5 -
Materials and Methods

Patients
Patients with MDS were divided into 2 groups using the International Prognostic Scoring System (IPSS):
lower-risk MDS includes low-or intermediate-1-risk MDS, and higher-risk MDS includes intermediate-2-
or high-risk MDS. Mutation analysis of RUNX1 was performed as described previously. 4 The study was approved by the institutional review board at Hiroshima University. Patients gave written informed consent for the study, according to the Declaration of Helsinki.
qRT-PCR
CD34 + cells were purified from patients using the CD34 MicroBead Kit and autoMACS system (Milteny Biotec, Bergisch Gladbach, Germany). Total RNA was harvested from the CD34 + cells using the RNeasy
Micro Kit (Qiagen, Hilden, Germany (gggttttcttggtgaagttcg/ttgcccatcatcatcacct), Evi1 (atcggaagatcttagatgagttttg/cttcctacatctggttgactgg) and Gapdh (gcattgtggaagggctcatg/ttgctgttgaagtcgcaggag).
Retroviral vectors and infection
RUNX1 (wild-type (WT) and D171N mutant) cDNA with FLAG tag was subcloned into the pMXs-IRES-EGFP (pMXs.IG). BMI1 was subcloned into the pMXs-IRES-DsRed-Express (pMXs.IR), in which the IRES-DsRed-Express fragment from the pIRES2-DsRed-Express (Clontech, Mountain View, CA) was inserted into the pMXs. FLAG-tagged D171N was also subcloned into pMYs-IRES-puro (pMYs.IP) and pMYs-IRES-EGFP (pMYs.IG), and BMI1 into pMYs-IRES-blasticidin (pMYs.IB) and pMYs-IRES-nerve growth factor receptor (NGFR) (pMYs.IN). Plat-GP and Plat-E packaging cells were transfected with retroviral constructs using FuGENE6 (Roche, Mannheim, Germany) as described previously.
16,22
Retrovirus transduction of human CD34 + primary cells Cells were cultured continuously in IMDM containing 20% FBS and 100 ng/mL each of FLT-3 ligand, SCF and TPO. For long-term growth, IMDM was supplemented with 20% FBS, 100 ng/mL each of FLT-3 ligand, SCF, and TPO, and 20 ng/mL each of IL-6 and IL-3 (Peprotech).
Colony forming cell (CFC) replating assay
Ten thousand sorted cells were resuspended in MethoCult H4034 + medium (StemCell Technologies, Vancouver, Canada) containing SCF, G-CSF, hGM-CSF, IL-3 and EPO. After 14 days in culture, colonies were counted. Cells were then suspended in methylcellulose medium, and 10 4 cells were plated again for CFC replating assay. Remaining cells were used for cell number counting and cytospin centrifuge for morphological and flow cytometry analyses.
Long-term culture-initiating cell (LTC-IC) assay
For bulk culture assay, 10,000 sorted cells were suspended in Myelocult H5100 medium (StemCell Technologies) with 1 μ M hydrocortisone (StemCell Technologies). The cells were divided into two dishes precoated with MS5 stromal cells and cultured for 5 weeks. LTC-IC cultures were harvested, and clonogenic progenitors were assayed in Methocult GF + H4435 medium (StemCell Technologies) containing SCF, GM-CSF, IL-3, IL-6, G-CSF and EPO. After 20 days, LTC-ICs derived CFCs were counted. For limiting dilution assay, 100 to 800 sorted cells per well were plated on MS5 stromal cells in 96-well plates and cultured as above. Wells were scored as growth or no growth of colonies. LTC-IC frequency was calculated with L-Calc software (StemCell Technologies).
Retroviral transduction of 32Dcl3 cells and differentiation assay
The murine myeloid progenitor 32Dcl3 cells were infected with retrovirus as previously described.
36
Mouse BMT
Mouse BMT was performed as described previously. 22 BM mononuclear cells were isolated from C57BL/6 (Ly-5.1) donor mice, and after stimulation with SCF, FLT3 ligand, IL-6 and TPO (R&D Systems), the cells were transduced with retrovirus constructs. Then, 3-5×10 5 of the non-sorted cells were injected into sublethally γ -irradiated Ly-5.2 recipient mice. These studies were approved by the Animal Care
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Flow cytometry
Human cells were stained with the indicated PE or APC-conjugated antibodies (BD). For the cell cycle analysis, the cells were stained with APC BrdU Flow Kit (BD) or Hoechst 33342 (BD). Flow cytometry analysis was performed on a FACSCalibur (BD) or FACS Aria and data were analyzed using CELLQuest.
Mouse cells were stained with the indicated PE-conjugated antibodies (eBioscience) and analyzed using FACSCalibur equipped with FlowJo Version 7.2.4 software (TreeStar). Annexin V staining was carried out with the PE Annexin V Apoptosis Detection Kit I (BD).
Immunoblot analysis
Immunoblot analysis was performed as reported previously. 12 The primary antibodies used in this study were anti-FLAG M2 (Sigma-Aldrich), anti-Bmi-1 (Upstate, Lake Placid, NY or #05-637, Millipore),
anti-β-Actin (Santa Cruz) and anti-α-tubulin (Sigma-Aldrich) monoclonal antibodies.
Statistical analysis
For comparison of two independent samples, normally-distributed variables were compared by the Student's t test and nonnormally-distributed variables by the Mann-Whitney U test. For multiple pairwise comparisons, the data were analyzed by one-way analysis of variance followed by Dunnett's multiple comparison test, or differences between individual groups were estimated using the Steel-Dwass test.
Survival curves were estimated by the Kaplan-Meier analysis and compared using the log-rank test. P < 0.05 was considered statistically significant.
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Results
RUNX1 D171 amino acid is the most frequent target of mutations
We analyzed RUNX1 mutations in various myeloid neoplasms, mostly MDS and MDS-related AML including therapy-related cases. We found that 107 patients had RUNX1 mutations, which were shown to be distributed throughout the full length of the RUNX1 protein (Table S1 ). Replacement of the D171 amino acid (D171N and D171G) was the most frequent target of mutation in the RUNX1 gene, which was detected in 8 (7.5 %) patients. The D171 residue resides in the RHD and is one of the critical amino acid residues that directly contact DNA, however, small changes in the RHD do not influence the ability for binding CBFβ. 20, 21 Moreover, the C-terminal region including the transactivation/repression domains is preserved in the mutations ( Figure S1A ), contrary to that in truncation type mutations. Replacement or small in-frame insertion/deletion at or around critical amino acid residues involved in DNA binding were also detected, and 41.6% of the RUNX1 mutations (45 of 107) had impaired DNA-binding but intact C-terminal transactivation/repression domains. The D171N mutant was localized to the nucleus ( Figure   S1B ) and showed a loss of normal RUNX1 trans-activation potential for the M-CSF receptor ( Figure   S1C ). Furthermore, the mutant displayed a dominant-negative type of trans-activation suppression ( Figure S1D ), suggesting that the mutant may have some oncogenic potential in addition to the loss of normal RUNX1 function.
EVI1 overexpression collaborates with RUNX1 mutation in human MDS
Because collaboration between RUNX1 mutations and Evi1 overexpression has been shown in a mouse BMT model, 22 we first checked EVI1 expression levels in selected CD34 + cells from MDS patients. Most of the examined patients showed very low EVI1 expression ( Figure 1A ). However, one patient whose initial diagnosis was MDS with D171G mutation displayed extremely high expression level of EVI1. The clinical course of the patient was unique in that a steep increase in blast cells was followed by a relatively short MDS period ( Figure 1B) , which was similar to that in the mouse BMT model. 22 Thus, expression of EVI1 is generally not high in MDS patients. Then, we set out to elucidate the collaborating genes with RUNX1 mutations in other patients.
Overexpression of D171N promotes inhibition of differentiation and increase in self-renewal capacity in human CD34 + cells
To clarify the biological functions of the RUNX1 mutants itself and to identify their collaborating genes in hematopoietic stem/progenitor cells, we transduced a RUNX1 mutant into human CD34 + cells to avoid For personal use only. at Sistema Bibliotecario d'Ateneo -Università degli Studi di Bologna on bloodjournal.hematologylibrary.org From -9 -the effect of Evi1 overexpression. The D171N mutant, which was produced by a 1-bp replacement in exon 5, was transduced into CD34 + cells from human CBs (Figure 2A ). The efficiency of transduction was about 30-60% ( Figure 2B ), and RUNX1 expression was confirmed by Western blotting ( Figure 2C ).
To examine the effect of RUNX1 expression on cell differentiation, we performed CFC assay by plating sorted cells in methylcellulose medium. The number of burst forming unit-erythroid (BFU-E) colonies was significantly decreased in both WT-and D171N-transduced cells, while the number of granulocyte-macrophage colony-forming unit (CFU-GM) colonies was not significantly different ( Figure   2D ). On the other hand, the individual BFU-E colonies in the WT plates and individual CFU-GM colonies in the D171N plates were larger in size ( Figure 2E ), in addition to the presence of significantly more growing cells as compared with control ( Figure 2F ). GPA + erythroid cells were dominant in the WT group, while most of the D171N-transduced cells expressed myeloid lineage markers ( Figure 2G ). To determine whether D171N have self-renewal advantage, we performed replating CFC assay. The plates of the D171N mutant contained approximately half the total number of colonies as the pMXs.IG plates in the 1st assay, while total cell numbers were comparable between the D171N and pMXs.IG plates ( Figure   2H ). Unlike pMXs.IG and WT, D171N showed replating capacity for three replatings. To confirm the presence of progenitors with long-term self-renewal capabilities, LTC-IC assay was conducted. Cells transduced with D171N showed a drastic increase in the number of colonies ( Figure 2I ).
D171N-transduced cells lack long-term proliferation ability in human CD34 + cells
To (Table   S2 ). Thus, it is suspected that the mutant requires additional gene alterations for the development of MDS.
BMI1 is overexpressed in CD34 + cells from MDS patients with RUNX1 mutations, while it is repressed in D171N-transduced human CD34 + cells
We focused on BMI1 as a candidate of the additional partner gene alterations because this gene is known to be overexpressed in some MDS patients. BMI1 expression levels were analyzed in selected These results raised the possibility that BMI1 may be overexpressed by additional molecular abnormalities and may work as a proliferative activator in the stem/progenitor cells with RUNX1
mutations. Since the D171N mutation itself was not proliferogenic, our next investigation was undertaken to determine whether BMI1 is required for leukemogenesis in the D171N-mutated cells.
BMI1 overexpression confers survival advantage but does not inhibit G-CSF-induced differentiation of 32D cells
To confirm the collaboration of D171N with BMI1, we first transduced both the D171N mutant and BMI1 (Table S2) . Therefore, to confirm the collaboration of BMI1 overexpression with D171N mutant in vivo, we performed mouse BMT using BM cells transduced with both D171N and BMI1. We previously (Table   1 and Figure 6C ). In the leukemic mice with D171N/pMYs.IN or D171N/BMI1, BM and spleen were occupied by immature myeloid cells including myeloid blasts ( Figure 6D ). More myeloblasts in BM were observed in D171N/BMI1 mice than in D171N/pMYs.IN ones ( Table 1 The biological functions of RUNX1 mutants, which have already been demonstrated using the mouse BMT model, include increase in leukemogenic potential. 22 In this model, however, the retrovirus frequently integrated into the chromosome near the Evi1 locus, resulting in its high expression. We checked EVI1 expression levels in MDS patients, however, most of the examined patients showed very low EVI1 expression except only one patient with RUNX1 mutation, who rapidly progressed from MDS to AML with hyperblastcytosis. Because collaboration between RUNX1 mutations and EVI1 overexpression does not appear to be common in MDS patients, we tried to clarify the biological significance of RUNX1 mutants in stem/progenitor cells using human CBs without the effect of Evi1 overexpression.
The cells transduced with wild-type RUNX1 quickly differentiated into mature myeloid/monocytoid cells without proliferation in both colony forming and liquid culture assays. This result suggests that overexpression of wild-type RUNX1 in stem/progenitor cells promotes terminal differentiation without self-renewal, blocks cell proliferation, and has no oncogenic potential. These data can explain the reduction in wild-type RUNX1-transduced cells in a mouse BMT model. 22, 38 On the other hand, the D171N mutant, the most common mutation in RUNX1 that is caused by only a 1-bp replacement in the RHD, has increased self-renewal capacity, mildly blocked differentiation, dysplasia in all 3 lineages, and slight tendency for immaturity, but no proliferation ability. Although a stem/progenitor cell with the D171N mutation is suspected to have MDS-genic potential of cell dysplasia and self-renewal capacity, it induces G1 arrest and cannot develop MDS due to lack of proliferation ability.
Thus, additional gene alterations that induce proliferation activity seem to be necessary for development of MDS. BMI1 overexpression was suspected as a candidate collaborator, since upregulated BMI1 level was observed in higher-risk MDS patients with RUNX1 mutations, even though the D171N mutant itself does not induce BMI1 expression. The molecular mechanism of high BMI1 expression in RUNX1-mutated patients is not due to microRNAs either. A previous study showed that forced expression of activated N-RAS mutant induced overexpression of Bmi1 in mouse c-Kit + cells, especially in Runx1 -/-cells. 39 Thus, the gene mutations that induce activation of the RAS signaling pathway, which overexpression may act as one of the partner abnormalities collaborating with master gene mutations for MDS-genesis. BMI1 affects INK4A/ARF expression, which has been sufficiently elucidated, involved in the leukemic phenotype. A previous report that showed that BMI1 collaborates with BCR-ABL in leukemic transformation also supports this idea. 47 We confirmed that significant enrichments of BMI1
were detected on Ink4a/Arf promoter regions in both BMI1-transduced cells and BMI1/D171N-transduced cells, suggesting that BMI1 overexpression may help cells transform, at least in part, due to suppressing the expression of the Ink4a/Arf tumor suppressor gene. Although a physical association in vivo between BMI1 and D171N, as well as wild type RUNX1, 48 was observed, it is known that D171N mutant has lost the DNA binding ability. 12 Therefore, the mechanism by which BMI1 co-expression with D171N mutant induces proliferative effects seems to be independent of the direct physical association between RUNX1 and BMI1. Additionally, both BMI1-knockdown human CD34 + cells
and Bmi1-deficient mouse cells showed elevated levels of reactive oxygen species accumulation, 49, 50 resulting in impairment of long-term expansion and apoptosis. It may be the reason why For expression, and Wright-Giemsa stained cytospins on day 39 as captured with a BX51 microscope and a DP12 camera (Olympus) at x400 and x1000 original magnifications.
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